Tetraphase has two suit­ors, de­spite strug­gling mar­ket for an­tibi­otics

The mar­ket for an­tibi­otics may be “bro­ken,” but one small an­tibi­ot­ic com­pa­ny is seem­ing­ly in de­mand: Tetraphase Phar­ma­ceu­ti­cals. In March, the com­pa­ny said it had agreed to be ac­quired by Acel­Rx in an all-stock deal val­ued at $14.4 mil­lion. But this week, an­oth­er drug­mak­er ap­pears to be court­ing Tetraphase — La Jol­la Phar­ma­ceu­ti­cals sub­mit­ted a non-bind­ing pro­pos­al to swal­low Tetraphase for $22 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.